- Research article
- Open Access
Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages
© Joshi et al; licensee BioMed Central Ltd. 2010
- Received: 19 August 2010
- Accepted: 19 October 2010
- Published: 19 October 2010
Interleukin-33 is a member of the IL-1 cytokine family whose functions are mediated and modulated by the ST2 receptor. IL-33-ST2 expression and interactions have been explored in mouse macrophages but little is known about the effect of IL-33 on human macrophages. The expression of ST2 transcript and protein levels, and IL-33-mediated effects on M1 (i.e. classical activation) and M2 (i.e. alternative activation) chemokine marker expression in human bone marrow-derived macrophages were examined.
Human macrophages constitutively expressed the membrane-associated (i.e. ST2L) and the soluble (i.e. sST2) ST2 receptors. M2 (IL-4 + IL-13) skewing stimuli markedly increased the expression of ST2L, but neither polarizing cytokine treatment promoted the release of sST2 from these cells. When added to naïve macrophages alone, IL-33 directly enhanced the expression of CCL3. In combination with LPS, IL-33 blocked the expression of the M2 chemokine marker CCL18, but did not alter CCL3 expression in these naive cells. The addition of IL-33 to M1 macrophages markedly increased the expression of CCL18 above that detected in untreated M1 macrophages. Similarly, alternatively activated human macrophages treated with IL-33 exhibited enhanced expression of CCL18 and the M2 marker mannose receptor above that detected in M2 macrophages alone.
Together, these data suggest that primary responses to IL-33 in bone marrow derived human macrophages favors M1 chemokine generation while its addition to polarized human macrophages promotes or amplifies M2 chemokine expression.
- Human Macrophage
- iNKT Cell
- Mouse Macrophage
- Mannose Receptor
- CCL18 Expression
Macrophages play a pivotal role in regulating the initiation, amplification, and resolution of innate immune responses. Several diseases including atherosclerosis, diabetes, cancer, and rheumatoid arthritis are associated with a defect or alteration in macrophage function . These cells arise in the bone marrow from granulocyte/macrophage progenitors, which are the precursors of monocytes. Monocytes exit the bone marrow and in turn respond to cytokines and chemokines during their recruitment into tissue where they differentiate into resident macrophages. Macrophages can be classically activated (i.e. M1) or alternatively activated (i.e. M2) based upon the response of these cells to the extracellular milieu . In the presence of IFN-γ and PAMPs such as LPS, macrophages become M1 activated while in the presence of Th2-type cytokines such as IL-4 and IL-13, macrophages undergo alternative activation or are skewed toward an M2 phenotype . Macrophage polarization dramatically alters the immune properties of these cells as evidenced by the potent anti-microbial properties of M1 macrophages versus the prominent tissue repair properties of M2 macrophages . Although M1 and M2 markers have been more thoroughly characterized in mouse macrophages [3, 4], human macrophages show selective soluble and cell membrane associated marker expression following exposure of these cells to M1 or M2 skewing conditions . Examples of chemokines/chemokines receptor markers that are selectively upregulated under M1 conditions include CCR7 and CCL3 whereas CCL18 is selectively upregulated under M2 conditions in human macrophages . Mannose receptor is a selective M2 marker in both mouse  and human  macrophages.
IL-33, similar to IL-1β and IL-18, is a member the IL-1 family that has a major role in innate immune responses driven through its receptor ST2 [7–10]. IL-33 is constitutively expressed by endothelial and epithelial cells and is found associated with chromatin in the nucleus . IL-33 is released by these cells following necrotic cell death, hence this cytokine has been referred to as an 'alarmin' [12, 13]. Several experimental models have shown that binding of recombinant IL-33 to ST2 leads to the induction of Th2 immune responses [14–16], but its effects on a number of non-adaptive immune cells have been well documented . Specifically, a recent study addressed the effects of IL-33 on mouse macrophages and showed that this cytokine amplifies the expression of M2 markers in these cells . Less is known about the immunomodulatory effects of IL-33 in human cells but this cytokine is known to enhance both Th1 and Th2 responses in human basophils, Th2 cells, iNKT cells, NK cells, mast cells, and eosinophils [19–22]. However, little is known about the effect of IL-33 on primary human macrophages.
Herein, we investigated whether human bone marrow-derived macrophages express ST2 and respond to IL-33, and whether the activation status of human macrophages alters the response by these cells to this cytokine. These studies showed that human macrophages express both the transmembrane form of ST2 (ST2L) and the soluble form of ST2 (sST2). Characterization of the effect of IL-33 on human macrophage activation suggested that it promoted M1 chemokine generation in naïve human macrophages but enhanced the expression of M2 chemokine markers in previously polarized macrophages, regardless of the prior polarization signals. Together, these data suggest that IL-33 has a direct effect on the expression of M1 and M2 chemokine markers in human macrophages.
Culture of human bone marrow-derived macrophages
An Institutional Review Board (IRB) at the University of Michigan Medical School approved the studies described below (Study Title: The effect of inflammatory disease states on growth, maturation, and gene expression patterns of bone marrow derived cells; Study eResearch ID: HUM00005609). Informed consent was not required for IRB approval of this study because bone marrow was collected at the University of Michigan Medical Center from patients undergoing various diagnostic tests and mononuclear cells and only the unused portions of these bone marrow samples were studied.
Each bone marrow sample was first subjected to a density gradient centrifugation over Ficoll-Paque™ Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) to isolate cells of myeloid origin. In order to establish a reproducible protocol for growing macrophages from human bone marrow, we tested several types of culture conditions, media, and growth factor combinations. The protocol that yielded both the greatest number and purity of macrophages is described herein. Briefly, bone marrow cells were plated onto 100 mm tissue culture dishes and 5 ml of Iscove's Modified Dulbecco's Medium (IMDM; Thermo Fisher Scientific Inc., Waltham, MA) supplemented with 10% fetal calf serum (FCS), 100 U/ml of penicillin, 100 μg/ml of streptomycin, β-mercaptoethanol, 25 ng/ml of macrophage colony stimulating factor (MCSF), 2.5 ng/ml of granulocyte monocyte colony stimulating factor (GMCSF), 50 ng/ml of stem cell factor (SCF), and 20 ng/ml of IL-3 was added. All cytokine growth factors were purchased from R&D Systems (Minneapolis, MN). Cells received 10 ml of fresh IMDM containing cytokine growth factors at day 3 after plating and cultured for a total of 7-10 days at 37°C in 10% CO2.
Prior to an experiment, spent media was removed from the cultured macrophages, the plate was washed with Ca+2 and Mg+2 free PBS to remove non-adherent cells, and the macrophage monolayer was incubated in Ca+2 and Mg+2 free PBS for 10 min on ice. Next, macrophages were dislodged via repetitive pipetting. The resultant cell suspension was centrifuged at 400-× g for 10 min. The cell pellet was suspended in IMDM containing FCS, 100 U/ml of penicillin, 100 μg/ml of streptomycin, and β-mercaptoethanol and plated at a density of 1 × 106/ml in triplicate wells of a 6-well tissue culture plate.
Flow cytometry of human macrophages
Bone marrow-derived human macrophages were washed once with buffer containing 0.2% BSA and 0.1% NaN3. FcR blocking reagent from Miltenyi Biotec was used to block Fc receptors. These cell suspensions were then stained with the one of the following antibodies or antibody combinations: FITC conjugated CD11b (BD Biosciences, San Jose, CA), PECy7-conjugated CD14 (eBiosciences; San Diego, CA), biotin-conjugated CD163 (BD Biosciences) followed by PECy5 conjugated streptavidin (BD Biosciences), or biotin-conjugated CD68 (BD Biosciences) followed by PECy5 conjugated streptavidin (BD Biosciences). Cells were fixed in 4% formalin and analyzed using Beckman Coulter FC500 and FlowJo Software (Tree Star Inc.; Ashland, OR).
Effect of IL-33 on M1 and M2 chemokine expression by human macrophages
In the first series of experiments, macrophages were polarized toward either a M1 or M2 phenotype using distinct stimuli. To skew macrophages toward the generation of M1 chemokine markers, triplicate wells (in a 6-well tissue culture plate) containing 2.5 × 105 cells were stimulated with 100 ng/ml of IFN-γ (PeproTech; Rocky Hill, NJ) combined with 1 μg/ml of LPS (Sigma-Aldrich; St. Louis, MO) for 24 h. To skew macrophages toward the generation of M2 chemokines, triplicate wells containing 2.5 × 105 cells with the combination of 10 ng/ml of IL-4 and 10 ng/ml of IL-13 (both from R&D Systems) for 24 h. In other experiments, macrophages were incubated with 10 ng/ml IL-33 (IL-33112-270; R&D) alone for 24 h. To study the effect of IL-33 on previously polarized macrophages, macrophages were activated in M1 or M2 conditions for 24 h. These cells were washed and exposed to 10 ng/ml of IL-33 alone, IL-33 in combination with M1 or M2 macrophage skewing cytokines, or the M1 or M2 cytokines alone for an additional 24 h in culture. In all experiments, cell-free supernatants were removed and individual wells were processed for immunocytochemistry, protein analysis by Western blotting, or quantitative RNA analysis.
Immunocytochemistry and Western blotting analysis of ST2
Macrophages were either fixed in 8-well Labtek tissue culture slides for immunocytochemistry or treated with protein lysis buffer in 6-well tissue culture plates prior to Western blotting analysis. Employing a standard immunocytochemistry technique, an anti-ST2 polyclonal antibody from ProSci (Poway, CA) was used to stain for ST2 in primary human macrophages exposed to media alone, IL-33, M1-polarizing mediators, or M2-polarizing mediators. IgG control groups were also included in this protocol. Standard Western blotting techniques were used to detect ST2L and sST2 in cytoplasmic and nuclear extracts from cultured naïve and M2-polarized macrophages.
To analyze gene expression, RNA was extracted from adherent human macrophages using TriZol (Invitrogen Life Technologies; Carlsbad, CA). RNA was then converted to cDNA using Murine Moloney Leukemia Virus reverse transcriptase (Invitrogen Life Technologies). The resulting cDNA was analyzed by real time q-PCR using the ABIPRISM 7700 detection system (Applied Biosystems, Foster City, CA). Premixed primer/probe reagents for CCR7 and CCL3 were purchased from Applied Biosystems. The primers used to detect mannose receptor were ACC TCA CAA GTA TCC ACA CCA TC and CTT TCATCA CCA CAC AAT CCT C. The primers used for the detection of CCL18 were TAC CTC CTG GCA GAT TCC AC and TTA GAA GAG GTG GCC TCC AG. The following forward and reverse primers were used for the detection of ST2: (forward) CAG GAA AGA AAT CGT GTG T, (reverse) GCC AAG AAC TGA CTG CCT. To further distinguish the soluble form of ST2 (sST2) from the membrane associated form of this receptor (ST2L) the following primers were used. Soluble ST2: (forward) AGG CTT TTC TCT TGT TTC CAG TAA TCG G; (reverse) CAG TGA CAC AGA GGG AGT TCA TAA AGT TAG A. ST2L: (forward) AGG CTT TTC TCT TGT TTC CAG TAA TCG G; (reverse) GGC CTC AAT CCA GAA CAT TTT TAG GAT GAT AAC. A SYBR green PCR mix was used to amplify ST2, ST2L, sST2, mannose receptor, CCL18. The expression of GAPDH was used as internal control for each PCR reaction.
Analysis of variance (ANOVA) and the Dunnett's test were used to detect statistical differences between control and polarized human macrophages with and without IL-33 treatment. P values of ≤ 0.05 were considered statistically significant.
M1 and M2 chemokine marker expression by human bone marrow-derived macrophages
ST2 expression by human macrophages exposed to either M1 or M2 conditions
Exogenous IL-33 blocked LPS-mediated induction of a M2 but not an M1 chemokine marker expression in human macrophages
Effect of IL-33 on macrophage M1 and M2 chemokine expression
Effect of IL-33 on human macrophages previously exposed to either M1 or M2 conditions
The present study demonstrates that human macrophages express ST2 and respond to the presence of IL-33. The expression of ST2, particularly the transmembrane form of this receptor, and to a lesser extent the soluble version of this receptor, was affected by the polarization of human macrophages either toward the expression of either M1 or M2 chemokine markers. Macrophages also showed differential responses to IL-33, which appeared to depend on the activation status of these cells. Naïve macrophages responded to IL-33 through the elaboration of M1 chemokine markers. Conversely, when added to M1 or M2 polarizing or polarized conditions, this IL-1 like cytokine promoted the expression of M2 chemokine markers in human macrophages. Together these findings suggest that there is a dynamic range of human macrophage responses to IL-33.
The ST2 gene encodes for two distinct isoforms: ST2L and sST2. ST2L is the transmembrane form of ST2 and is the active IL-33-signaling receptor while the soluble form of this receptor is thought to function as a soluble decoy for IL-33. Both ST2 isoforms are expressed by a number of innate and adaptive immune cells and their expression is altered by cytokine signals (including IL-33 itself) in both types of immune cells . Regarding mouse macrophages, both forms of ST2 have been described in these cells although we have previously observed that ST2L levels are higher in alternatively activated or M2 mouse macrophages . These data are consistent with the observation that exogenous IL-33 amplifies the polarization of alternatively activated macrophages . In the present study, both ST2L and sST2 transcript and protein expression were examined in human macrophages. Both forms of ST2 were present in naïve human macrophages although sST2 was never detected in the cell-free supernatants from these cultures (data not shown). Both M1 and M2 polarizing mediators promoted the transcript expression of ST2L but not sST2 whereas the M2 polarizing conditions increased protein expression for both forms of ST2. These data are consistent with previous mouse macrophage data and highlight that ST2 expression is prominent on human M2 macrophages, but it is also expressed by naïve and M1 macrophages as well.
In contrast to earlier findings that functional IL-33 was a product of caspase-1 cleavage , it is now established that this cytokine is active without proteolysis and is inactivated by apoptotic caspases [8–10, 26]. Full length IL-33 (IL-331-270) is released from necrotic cells  or by activated mouse macrophages  independent of caspase or calpain activity. A truncated version of IL-33 (IL-33112-270) is formed via the activity of caspase 1 but it appears to lack the full potency of full length IL-33 . At the time these studies were undertaken, recombinant commercial sources of IL-33 were limited to IL-33112-270 thus this was the form of IL-33 used in cultures of human macrophages. Key observations from the present study included the M1 skewing effect of recombinant IL-33 on naïve human macrophages as evidenced by enhanced CCL3 expression. The inhibitory effect of IL-33 on LPS-induced CCL18 expression was consistent with the documented inhibitory effect of ST2 activation on TLR4 signaling [23, 28]. However, IL-33 had no inhibitory effect on the expression of CCL3 by naïve human macrophages, data that was consistent with studies in mouse macrophages indicating that IL-33 did not inhibit LPS activation of these cells . Thus, the addition of recombinant IL-33 to naïve human macrophages appeared to skew these cells toward the expression of M1 chemokine markers.
When added to macrophage cultures containing polarizing or polarized conditions, it was apparent that IL-33 had a divergent effect from that observed in cultures of naïve human macrophages. Specifically, IL-33 promoted or amplified M2-associated markers such as CCL18 and mannose receptors in these cells. These data are consistent with a previously published study showing that IL-33 amplifies the polarization of alternatively activated or M2 mouse macrophages  and contributes to Th2 responses [14, 29]. At present, an explanation of the M2 skewing properties of IL-33 in polarizing or polarized human macrophages is not clear, but further studies will be directed at exploring the role of CCL18 in this process. CCL18 has no known mouse homolog and it has been described as a potent inducer of alternative activation in human macrophages thereby promoting fibrotic responses in the lung [30, 31]. Thus, IL-33 uniquely promoted the expression of M2 chemokine markers in macrophages previously exposed to M1 or M2 conditions.
this study addressed the effect of IL-33 on the activation and polarization of primary human macrophages. These findings point to a dual effect of IL-33 that depends on the activation status of these cells, findings that are consistent with those of Smithgall and colleagues  who demonstrated that IL-33 amplified both Th1 and Th2 type responses in human immune cells. Thus, the present findings highlight the complex immunomodulatory role of this cytokine on human macrophages.
Centocor, Incorporated and the University of Michigan Medical School provided funding for the present study. The authors thank Dr. Judith Connett for her critical reading of the manuscript.
- Ross R, Ross XL, Ghadially H, Lahr T, Schwing J, Knop J, Reske-Kunz AB: Mouse langerhans cells differentially express an activated T cell-attracting CC chemokine. J Invest Dermatol. 1999, 113: 991-8. 10.1046/j.1523-1747.1999.00803.x.View ArticlePubMedGoogle Scholar
- Martinez FO, Sica A, Mantovani AM: Locati: Macrophage activation and polarization. Front Biosci. 2008, 13: 453-61. 10.2741/2692.View ArticlePubMedGoogle Scholar
- Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25: 677-86. 10.1016/j.it.2004.09.015.View ArticlePubMedGoogle Scholar
- Mantovani A, Sica A, Locati M: Macrophage polarization comes of age. Immunity. 2005, 23: 344-6. 10.1016/j.immuni.2005.10.001.View ArticlePubMedGoogle Scholar
- Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006, 177: 7303-11.View ArticlePubMedGoogle Scholar
- Stein M, Keshav S, Harris N, Gordon S: : Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992, 176: 287-92. 10.1084/jem.176.1.287.View ArticlePubMedGoogle Scholar
- Arend WP, Palmer G, Gabay C: IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008, 223: 20-38. 10.1111/j.1600-065X.2008.00624.x.View ArticlePubMedGoogle Scholar
- Cayrol C, Girard JP: The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009, 106: 9021-6. 10.1073/pnas.0812690106.PubMed CentralView ArticlePubMedGoogle Scholar
- Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G: Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009, 284: 19420-6. 10.1074/jbc.M901744200.PubMed CentralView ArticlePubMedGoogle Scholar
- Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K, Vandenabeele P, et al.,: Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009, 31: 84-98. 10.1016/j.immuni.2009.05.007.View ArticlePubMedGoogle Scholar
- Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007, 104: 282-7. 10.1073/pnas.0606854104.PubMed CentralView ArticlePubMedGoogle Scholar
- Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H, Haraldsen G: Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008, 173: 1229-42. 10.2353/ajpath.2008.080014.PubMed CentralView ArticlePubMedGoogle Scholar
- Moussion C, Ortega N, Girard JP: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS One. 2008, 3: e3331-10.1371/journal.pone.0003331.PubMed CentralView ArticlePubMedGoogle Scholar
- Kearley J, Buckland KF, Mathie SA, Lloyd CM: Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med. 2009, 179: 772-81. 10.1164/rccm.200805-666OC.PubMed CentralView ArticlePubMedGoogle Scholar
- Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, J Qin, X Li, et al.,: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005, 23: 479-90. 10.1016/j.immuni.2005.09.015.View ArticlePubMedGoogle Scholar
- Pushparaj PN, Tay HK, H'Ng CS, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ: The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009, 106: 9773-8. 10.1073/pnas.0901206106.PubMed CentralView ArticlePubMedGoogle Scholar
- Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, Hoshino T, Fujimoto J, Nakanishi K: Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008, 20: 791-800. 10.1093/intimm/dxn037.View ArticlePubMedGoogle Scholar
- Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, McKenzie AN, Kanellopoulos J: IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol. 2009, 183: 1446-55. 10.4049/jimmunol.0803067.View ArticlePubMedGoogle Scholar
- Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, Gombert JM, Schneider E, M Dy, Gourdy P, et al.,: The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol. 2009, 39: 1046-55. 10.1002/eji.200838575.View ArticlePubMedGoogle Scholar
- Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE: IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008, 20: 1019-30. 10.1093/intimm/dxn060.View ArticlePubMedGoogle Scholar
- Xu D, Jiang HR, Kewin P, Li Y, R Mu, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, et al.,: IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008, 105: 10913-8. 10.1073/pnas.0801898105.PubMed CentralView ArticlePubMedGoogle Scholar
- Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, Saito H, Matsushima K, Ohta K, Yamamoto K, et al.,: Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. 2008, 88: 1245-53. 10.1038/labinvest.2008.82.View ArticlePubMedGoogle Scholar
- Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, Liew FY: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol. 2004, 5: 373-9. 10.1038/ni1050.View ArticlePubMedGoogle Scholar
- Joshi AD, Raymond T, Coelho AL, Kunkel SL, Hogaboam CM: A systemic granulomatous response to Schistosoma mansoni eggs alters responsiveness of bone-marrow-derived macrophages to Toll-like receptor agonists. J Leukoc Biol. 2008, 83: 314-24. 10.1189/jlb.1007689.View ArticlePubMedGoogle Scholar
- Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N, et al.,: IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009, 183: 6469-77. 10.4049/jimmunol.0901575.View ArticlePubMedGoogle Scholar
- Ali S, Nguyen DQ, Falk W, Martin MU: Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun. 2010, 391: 1512-6. 10.1016/j.bbrc.2009.12.107.View ArticlePubMedGoogle Scholar
- Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, Okumura K, Saito H, Nakae S: Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol. 2009, 183: 7890-7. 10.4049/jimmunol.0802449.View ArticlePubMedGoogle Scholar
- Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V, Campbell CC, Xu D, Liew FY: A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol. 2001, 166: 6633-9.View ArticlePubMedGoogle Scholar
- Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H: IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009, 123: 1047-54. 10.1016/j.jaci.2009.02.026.PubMed CentralView ArticlePubMedGoogle Scholar
- Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G: A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. Am J Respir Crit Care Med. 2006, 173: 781-92. 10.1164/rccm.200509-1518OC.View ArticlePubMedGoogle Scholar
- Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Muller-Quernheim J: Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2009, 179: 717-723. 10.1164/rccm.200808-1201OC.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.